The new kerstar of irritable bowel syndrome (IBS) - probiotic-assisted therapy

Irritable Bowel Syndrome (IBS) is a common disease of gastrointestinal structure and bio-chemical dysfunction that, according to the newly released Roman IV standard in 2016, is clinically manifested as a group of persistent or intermittent episodes of abdominal pain, bloating, and diseases associated with changes in bowel conditions. IBS can be divided into four clinical types, diarrhea type (IBS-D), constipation type (IBS-C), mixed type (diarrhea, constipation alternating) and indetermation type according to the type.The prevalence of IBS in the general population in China is about 1.5%-11.5%, the prevalence rate of women is higher than that of men, of which only 25% of IBS patients go to the hospital for medical treatment. The study found that there was no obvious correlation between IBS incidence and population differences, which were generally caused by changes in intestinal dynamics, high sensitivity of the internal organs, imbalance of intestinal bacteria, psychological factors, etc. According to the Roman IV standard, the main treatment methods of IBS include complementary and alternative therapy, psychotherapy, drug therapy (laxatives, general medicine, etc.) and micro-ecological/immunomodulative therapy.November 2020, the probiotic-assisted treatment of IBS, written by the Coto Biodefragtic Research and Development Team, was successfully published in the international authoritative journal European Journal of Nutrition.How do probiotics aid in the treatment of IBS?test methodChinese 45 IBS patients were randomly divided into control group (21) and probiotic group (24) at the Navy General Hospital of the People's Liberation Army in Beijing.the control group was given conventional basic treatment, while the probiotic group was given conventional basic treatment and probiotic combined therapy. Each person takes Probio-Fit ® 2g (10 billion CFU) daily for 28 days. Take stool samples, blood samples for testing, and assess clinical improvement.Probio-Fit® contains Bacillus cheese, plant Lactobacillus P-8 and C.D.Tyrobacteria V9 1. Blood indicatorsCytolebin 8 (IL-8), tumor necrosis factor α (TNF-α), cytolebin 6 (IL-6) and D-lactic acid and other concentrations were significantly reduced, and blood indicators were significantly improved.2. Quality of life score and clinical symptom scoreThe quality of life score of patients in the probiotic group increased significantly, and the clinical symptom score also improved significantly, indicating that probiotics contribute to the mitigation of IBS.3. Intestinal bacterial diversitysignificantly improve the decline of intestinal bacteria diversity caused by IBS in patients with probiotic groups, and effectively enhance intestinal microbiobiosis.4. Intestinal bacterium structureReduce the amount of harmful bacteria such as citric acid genus and E. coli genus in the intestines of probiotic group patients, improve the structure of intestinal bacterium, and change the enterobacteria category of IBS patients (mainly Platts genus and Bacillus aegypti).theprobiotic preparation Probio-Fit® combined with conventional drug therapy, can reduce pathogenic cytokine levels, improve quality of life, improve IBS symptoms and related scores. Effectively regulate the gut bacteria and prevent the reduction of beneficial bacteria caused by IBS.Coto BiosFocus Chinese on intestinal health, through continuous efforts to build Asia's largest library of strains of bacteria, the preservation of lactic acid bacteria and Bifidobacteria more than 20,000 strains. More than 100 patents have been filed around the Star strain and more than 300 documents have been published.2016, Coto Bio has conducted 37 clinical trials around star strains in more than a dozen hospitals in China, with remarkable clinical results and many recommendations from doctors in China.published in European Journal of Nutrition (2020) DOI:10.1007/s00394-020-02437-4References:2020 Expert Consensus opinion on irritable bowel syndrome in China; 2020, 40 (12): 803-818 . Rome IV: Functional gastroenterology. Volume II: 4th edition of the original book /(US) Drossman editor-in-chief; Beijing: Science Press, 2016